Record-Breaking Ebola Treatment Trial Enrolls First Patients in DRC

The first patients have been enrolled in a groundbreaking Ebola treatment trial in the Democratic Republic of the Congo (DRC), just six weeks after the outbreak was declared a public health emergency by the World Health Organization (WHO) on May 17. The trial aims to test two experimental drugs in the Ituri region, where the virus continues to spread rapidly.

Ebola Treatment Trial Details

As of July 9, there have been 1,792 confirmed cases and 625 deaths due to the Bundibugyo strain of Ebola. The trial, known as the Partners treatment trial, includes two drugs: remdesivir, an antiviral developed by Gilead Sciences, and MBP134, a monoclonal antibody created by Mapp Biopharmaceutical. Patients will be assigned to receive either of the drugs, a combination, or standard supportive care.

“These two drugs actually have been proven to work against the Bundibugyo virus in animal models,” said Prof. Laurens Liesenborghs from the Institute of Tropical Medicine, Antwerp. “They showed great efficacy, but now we need to test it in humans.”

Community Response and Challenges

In Bunia, the capital of Ituri province, local residents express urgency for the trial's success. Neema Haba, a banana seller and mother of three, stated, “I hope these drug trials proceed quickly. Financially, we are being driven to the brink by this outbreak.” However, community mistrust and logistical issues, including a lack of pay for frontline workers, hinder the response efforts.

Ovide Maliabo, a driver for an Ebola burial team, described the dangers of their work amid community hostility, saying, “At one point, we narrowly escaped being lynched.” Bahati John, head of the burial team, added, “We haven’t seen a single penny since we started working on May 15.”

Future of Ebola Treatment

The WHO has confirmed that enough supplies of remdesivir and MBP134 have been donated for 1,200 patients to be enrolled in the trial. Researchers expect to enroll between 700 and 1,000 patients, with initial results anticipated in the coming months. “We need to see a substantial drop in mortality rates,” Liesenborghs concluded.

With the DRC's Ebola outbreak still in the expansion phase, effective treatments are critical to combating the virus and improving survival rates among patients.